Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Merus
Merus
Gilead tries new triple-target T-cell engagers in $1.5B-plus Merus collab
Fierce Biotech
Wed, 03/6/24 - 11:30 am
Gilead Sciences
Merus
T-cell engager
ASCO: Merus' gene-targeting cancer drug shrinks tumors. Will execs go it alone or partner?
Fierce Biotech
Tue, 06/7/22 - 10:16 am
ASCO 2022
Merus
zenocutuzumab
NRG1 fusion-positive cancer
#ASCO21: Eli Lilly-partnered Merus reveals new data for NRG1 fusion cancers including pancreatic and NSCLC
Endpoints
Sat, 06/5/21 - 02:17 pm
ASCO 2021
Merus
Eli Lilly
clinical trials
solid tumors
Eli Lilly tees up discovery pact worth more than $1.6B with Merus for T cell-focused bispecific antibodies
Endpoints
Tue, 01/19/21 - 10:39 am
Eli Lilly
oncology
Merus
drug discovery
Merus charts early promise for cancer drug targeting NRG1 fusions
Fierce Biotech
Mon, 10/28/19 - 10:40 am
Merus
bispecific antibodies
zenocutuzumab
NRG1 fusion
4 Stocks Battling Breast Cancer
Motley Fool
Sat, 10/26/19 - 02:18 pm
Seattle Genetics
Macrogenics
Merus
Zymeworks
Top Presentations to Look for at ASCO
Yahoo/24-7 Wall St
Tue, 05/30/17 - 11:35 am
ASCO 2017
Merck
AbbVie
Eli Lilly
Bluebird Bio
Epizyme
Juno Therapeutics
Kite
Merus
Incyte puts up $200M in bispecifics deal with Merus
BioPharma Dive
Thu, 12/22/16 - 10:21 am
Incyte
Merus
bispecific antibodies
Big Pharma-backed Dutch immuno-oncology player eyes €100M Nasdaq IPO
Fierce Biotech
Thu, 04/9/15 - 10:01 am
IPOs
Merus
JNJ
Novartis
Pfizer
immuno-oncology
J&J makes an R&D splash with $42M venture play, biotech collaborations
Fierce Biotech
Thu, 10/3/13 - 05:35 pm
R&D
JNJ
Effimune
Merus
Novartis Venture Fund
Pfizer Venture Investments